Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nafamostat mesilate in early mild COVID-19
jRCTs031210183Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of Nafabelltan in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: AUC of SARS-CoV-2 virus reduction in the nasopharynx from before the start of treatment to the 6th day of treatment. Started Jan 2022; status: completed.
02
Drugs
Nafabelltan
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCTs031210183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031210183.